SCHEMBL25965763

SCHEMBL25965763

CSC(C)OC(=O)n1cc(F)c(=O)[nH]c1=O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ MAPK3 P27361 1/20 0.42
▸ ASAH1 Q13510 1/20 0.42
▸ SQOR Q9Y6N5 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ GRIA1 P42261 1/20 0.41
▸ GRIA2 P42262 1/20 0.41
▸ GRIA3 P42263 1/20 0.41
▸ GRIA4 P48058 1/20 0.41
▸ GRIK5 Q16478 1/20 0.41
▸ KMT2A Q03164 1/20 0.36
▸ HPGD P15428 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ PMP22 Q01453 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23322830 0.85 LMNA (0.46) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL11159032 0.83 LMNA (0.44) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL11040533 0.83 LMNA (0.44) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL11024545 0.75 LMNA (0.61) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL15616807 0.74 LMNA (0.46) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL11739898 0.71 LMNA (0.49) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL10459041 0.71 LMNA (0.56) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL10656213 0.69 SMN1; SMN2 (0.57) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL11741360 0.69 LMNA (0.61) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3
SCHEMBL7915827 0.69 LMNA (0.49) LMNASMN1; SMN2CYP3A4CYP2D6MAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230256109-A1 Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy TAMBO, INC. 2023-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230256109-A1 Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy ICOS, CD74, PBK LMNA 4665/4885SMN1; SMN2 4078/4885CYP3A4 3169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback